key: cord-0914105-jz0h28es
authors: Wolff, Fleur; Dahma, Hafid; Duterme, Cécile; Van den Wijngaert, Sigi; Vandenberg, Olivier; Cotton, Frédéric; Montesinos, Isabel
title: Monitoring antibody response following SARS-CoV-2 infection: Diagnostic efficiency of four automated immunoassays
date: 2020-07-12
journal: Diagn Microbiol Infect Dis
DOI: 10.1016/j.diagmicrobio.2020.115140
sha: ed19765f5db57e8b849e73f9f9c82bda9f6f1be7
doc_id: 914105
cord_uid: jz0h28es

INTRODUCTION: SARS-CoV-2 seroconversion is important for epidemiological studies as well as contact tracing. MATERIAL AND METHODS: The antibody response against SARS-CoV-2 was examined in 111 patients with a positive qRT-PCR. Seroconversion was assessed using the Elecsys from Roche, the Liaison S1/S2 IgG from Diasorin, the IgG and IgA from Euroimmun as well as the VIDAS IgG and IgM. Specificity was estimated based on the measurement of SARS-CoV-2 antibodies in 96 residual samples collected during a non-pandemic period. RESULTS: The highest overall sensitivity for detecting seroconversion was obtained using the Elecsys (81.1%), the Euroimmun with a combined detection of IgG/IgA (86.5%) and the VIDAS with a simultaneous measurement of IgG/IgM (78.4%).The Elecsys and the VIDAS IgG/IgM demonstrated a specificity as well as a positive predictive value of 100%. CONCLUSIONS: The Elecsys and the VIDAS methods with a combination of IgG/IgM measurement demonstrated a high sensitivity with no false positive results.

Introduction SARS-CoV-2 seroconversion is important for epidemiological studies as well as contact tracing.

The antibody response against SARS-CoV-2 was examined in 111 patients with a positive qRT-PCR. Seroconversion was assessed using the Elecsys from Roche, the Liaison S1/S2 IgG from Diasorin, the IgG and IgA from Euroimmun as well as the VIDAS IgG and IgM.

Specificity was estimated based on the measurement of SARS-CoV-2 antibodies in 96 residual samples collected during a non-pandemic period.

The highest overall sensitivity for detecting seroconversion was obtained using the Elecsys (81.1%), the Euroimmun with a combined detection of IgG/IgA (86.5%) and the VIDAS with a simultaneous measurement of IgG/IgM (78.4%).The Elecsys and the VIDAS IgG/IgM demonstrated a specificity as well as a positive predictive value of 100%.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus infectious disease , recently declared by the World Health Organization (WHO) as a global pandemic [1] . Besides the molecular diagnosis using nucleic acid amplification, the serology is a complementary method potentially filling the gap of false negative ribonucleic acid (RNA) and allowing the rapid screening of individuals at a larger scale. Both techniques are essential to guide antiviral treatment, epidemiological measures, vaccination when available and consequently to control the disease by applying appropriate lockdown exit strategies [2, 3] .

Different commercial serological tests are available for monitoring the antibody response following a SARS-CoV-2 infection. Enzyme linked immunosorbent assays (ELISA), chemiluminescent immunoassays (CLIA) as well as enzyme linked fluorescence assays (ELFA) are the main methodologies available for automated analytical platforms [4, 5, 6] .

Potential antigens for serodiagnosis of COVID-19 differ; some of them are based on a recombinant SARS-CoV-2 nucleocapsid protein, while others use a recombinant spike protein. Furthermore, IgG, IgA, IgM, or a combination of different classes of immunoglobulins (i.e. IgG /IgM) can be measured.

In this study, the diagnostic efficiency of four anti-SARS-CoV-2 automated immunoassays detecting different classes of immunoglobulins was evaluated: Elecsys Anti-SARS CoV-2 (Roche Diagnostics, Vilvoorde, Belgium), Liaison SARS-CoV-2 S1/S2 IgG (Diasorin, J o u r n a l P r e -p r o o f 9 allow a determination of IgG and IgA against the SARS-CoV-2. The microplate wells are coated with recombinant S1 structural protein. The results are evaluated by calculation of a ratio of the extinction of samples over the extinction of the calibrator. The ratio interpretation was as follows: <0.8 = negative, ≥ 0.8 to < 1.1 = borderline, ≥ 1.1 = positive. Borderline data were considered positive for the statistical analyses.

The VIDAS Anti-SARS CoV-2 is a two-step sandwich ELFA performed on a VIDAS analyzer (BioMérieux, Marcy-l'Etoile, France). The IgG and IgM in the sample are captured by a recombinant SARS-CoV-2 sub domain spike antigen coated on a solid phase, then an anti-human IgG or IgM labeled with alkaline phosphatase is added. The intensity of the fluorescence produced by the substrate hydrolysis is measured at 450 nm and is proportional to the antibody level. An index is calculated as the ratio between the relative fluorescence value (RFV) measured in the sample and the RFV obtained for the calibrator (humanized recombinant anti-SARS CoV-2 IgG or IgM) and interpreted as negative (index<1) or positive (index≥1).

The principle of antibody detection, the recombinant antigen used, the immunoglobulin classes recognized, the kit format, the samples throughput as well as the time to the first result of the different commercial immunoassays for monitoring antibodies production are described in table 1.

Results were analyzed using the Graph Pad Prism software version 5.0 (La Jolla, USA).

Median and range were used for describing continuous variables. Receiver operator characteristic (ROC) curve was calculated and the area under the curve (AUC) obtained was reported for each assay. The Youden index was calculated to select the optimal threshold value giving the best combination of sensitivity and specificity. [7] . Monitoring antibody response could be complementary to nucleic acid testing given the potential false negative RNA results. Combining RNA and antibody measurement significantly increases the positive detection rate in patients [8] .

Compared to molecular methods, most serological tests present a faster turn-around time, high-throughput and less workload [9] . Seroconversion assessment could allow the identification of individuals exposed to the virus as well as potentially protected people and as a consequence, could guide the application of progressive relaxation of containment measures [3] .

Many CE-labeled tests allowing the detection of SARS-CoV-2 antibodies are now available on the market. They differ in the type of immunoglobulin classes recognized (IgA, IgM, IgG or a combination IgM/IgG) as well as the nature of the antigen used for antibody recognition.

Some of them are based on a recombinant nucleocapsid protein (i.e. the Elecsys Roche) while others use of a recombinant spike protein (i.e. Spike-S1/S2 protein for the Liaison, Spike-S1 protein for the Euroimmun IgG and IgA, sub domain of Spike protein for the VIDAS IgG and IgM), both proteins being highly immunogenic [10] . A higher sensitivity was described for Conflicting results are described in the literature regarding the chronological order of IgM as well as IgG appearance following a SARS-CoV-2 infection and could be explained by the different sensitivity of immunoassays [2] . Whereas some authors demonstrated that the dynamic pattern of SARS-CoV-2 antibody production is typical of acute viral infection with a rise of IgG that appears when IgM drop [8, 9, 11, 13] , others showed an earlier conversion for IgG than IgM [2, 5, 14] . This contradictory data support the detection on both antibodies simultaneously [12] . patients. However, these data were obtained in a limited number of patients (i.e. 11 nonsevere and 5 severe cases) [7] . In this study, the detection rates of SARS-CoV-2 obtained using the different assays were compared according to the clinical presentation of the disease (i.e. none symptom, mild to moderate COVID-19 disease and severe COVID-19 disease).

Although, no significant difference in sensitivity as well as serum antibody levels was underlined for mild/moderate versus severe patients, a lower detection rate was obtained for asymptomatic carriers regardless of the immunoassays used. This different pattern of To conclude, combining molecular diagnosis and serological tests could enhance the detection of infected individuals, an accurate diagnosis being essential to limit the spread of SARS-CoV-2 [8, 9] . The choice of the most appropriate immunoassay for assessing SARS-CoV-2 seroconversion will be guided by its diagnostic efficiency but also by its capacity for samples J o u r n a l P r e -p r o o f 

European Centre for disease Prevention and Control (ECDC) (2019). Geographical distribution

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Preparing for a responsible lockdown exit strategy

Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies

Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics

Assessment of immune response to SARS-CoV-2 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays

Different Longitudinal Patterns of Nucleic Acid and Serology Testing Results Based on Disease Severity of COVID

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease

Laboratory diagnosis of emerging human coronavirus infections-the state of the art

Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2

Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice

Severe acute respiratory syndrome coronavirus 2-specific antibody responses in Coronavirus disease 2019 patients

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes